{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:47Z","timestamp":1791613667322,"version":"4.3.4"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with relapsed\/refractory multiple myeloma (RRMM) that are refractory to the five most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal outcomes with subsequent therapies. Progressive immune dysfunction, particularly of the T-cell repertoire, is implicated in the development of disease progression and refractory disease. However, the advent of novel immunotherapies such as bispecific antibodies are rapidly changing the treatment landscape and improving the survival outcomes of patients with RRMM. Bispecific antibodies are antibodies that are engineered to simultaneously engage cytotoxic immune effector cells (T cells or NK cells) and malignant plasma cells via binding to immune effector cell antigens and extracellular plasma cell antigens leading to immune effector cell activation and malignant plasma cell destruction. Currently, bispecific antibodies that bind CD3 on T cells and plasma cell epitopes such as B-cell maturation antigen (BCMA), G-protein coupled receptor family C group 5 member D (GPRC5d), and Fc receptor homologue 5 (FcRH5) are the most advanced in clinical development and are showing unprecedented response rates in patients with RRMM, including patients with penta-refractory disease. In this review article, we explore the available clinical data of bispecific antibodies in RRMM and summarize the efficacy, safety, toxicity, clinical outcomes, mechanisms of resistance, and future directions of these therapies in patients with RRMM.<\/jats:p>","DOI":"10.3389\/fonc.2024.1394048","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T05:20:05Z","timestamp":1712726405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma: updates and future perspectives"],"prefix":"10.3389","volume":"14","author":[{"given":"Ricardo D.","family":"Parrondo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1182\/blood-2021-153556","article-title":"Inferior outcomes of patients with quad and penta-refractory multiple myeloma (MM) compared to those of patients who have been quad and penta exposed","volume":"138","author":"Gill","year":"2021","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-022-00733-2","article-title":"I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients","volume":"12","author":"Gill","year":"2022","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1182\/blood-2018-99-117713","article-title":"D.C.E.P. @ in patients with quad- or penta-refractory multiple myeloma","volume":"132","author":"Goldsmith","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08034.x","article-title":"Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma","volume":"148","author":"Michalek","year":"2010","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202491499","article-title":"T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.651","article-title":"Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: teclistamab (tec) + nirogacestat (niro) in relapsed\/refractory multiple myeloma (rrmm): the phase 1b majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a Phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1182\/blood-2023-177735","article-title":"A phase 2, single-arm, non-inferiority study of limited-duration teclistamab for relapsed and refractory multiple myeloma (LimiTec)","volume":"142","author":"Razzo","year":"2023","journal-title":"Blood"},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1182\/blood-2023-185257","article-title":"Optec: A phase 2 study to evaluate outpatient administration of teclistamab, a BCMA-targeting bispecific antibody, in patients with multiple myeloma","volume":"142","author":"Rifkin","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2023-174270","article-title":"Real-world treatment outcomes of teclistamab under an outpatient model for step-up dosing administration","volume":"142","author":"Sandahl","year":"2023","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab prophylaxis for patients treated with teclistamab: A single-center experience","volume":"142","author":"Kowalski","year":"2023","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1182\/blood-2023-180660","article-title":"Teclistamab in relapsed refractory multiple myeloma patients on dialysis: A French experience","volume":"142","author":"Lachenal","year":"2023","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843628.63947.e4","article-title":"S184: evaluating teclistamab in patients with relapsed\/refractory multiple myeloma following exposure to other b-cell maturation antigen (bcma)-targeted agents","volume":"6","author":"Touzeau","year":"2022","journal-title":"HemaSphere"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180421","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: A real-world experience","volume":"30","author":"Dima","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2023","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1610068","DOI":"10.1097\/01.HS9.0000967700.16100.68","article-title":"S197: linker-mm1 study: linvoseltamab (regn5458) in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"HemaSphere"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood.V130.Suppl_1.501.501","article-title":"T Cell Engagement without Cytokine Storm: A Novel Bcma x CD3 Antibody Killing Myeloma Cells with Minimal Cytokine Secretion","volume":"130","author":"Buelow","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.69","article-title":"Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed\/refractory multiple myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"EJHaem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2 + 1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01883-3","article-title":"Preclinical discovery and initial clinical data of WVT078, a BCMA \u00d7 CD3 bispecific antibody","volume":"37","author":"Raab","year":"2023","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1182\/blood-2023-177908","article-title":"Initial results from a phase 1 dose-escalation study of WVT078, a BCMA\u00d7CD3 bispecific antibody, in combination with WHG626, a gamma-secretase (GS) inhibitor, in patients with relapsed and\/or refractory multiple myeloma","volume":"142","author":"Schjesvold","year":"2023","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 monumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 monumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b monumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843624.82943.92","article-title":"S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED\/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB","volume":"6","author":"van de Donk","year":"2022","journal-title":"HemaSphere"},{"key":"B60","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1538-7445.AM2023-843","article-title":"Abstract 843: Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma","volume":"83","author":"Santini","year":"2023","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B66","volume-title":"P946: tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (rrmm) who receive cevostamab. Lid - e75458a8. (2572-9241 (electronic))","author":"Mateos","year":"2023"},{"key":"B67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological Malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019451","article-title":"Preclinical characterization of ISB 1342, a CD38 \u00d7 CD3 T-cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2023-186664","article-title":"Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Kapoor","year":"2023","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162201","article-title":"Preclinical evaluation of ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of AML and T-ALL","volume":"140","author":"Stefano","year":"2022","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1182\/blood-2023-186241","article-title":"Initial dose escalation of ISB 1442, a novel CD38 biparatopic x CD47 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Kazandjian","year":"2023","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2023-182150","article-title":"A CD38\/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent in multiple myeloma patients relapsed and\/or refractory (RRMM) to anti-CD38 monoclonal antibodies (mAbs)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1158\/1538-7445.AM2023-2970","article-title":"Abstract 2970: Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager","volume":"83","author":"Pihlgren","year":"2023","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159665","article-title":"Updated interim results from a phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Abdallah","year":"2022","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164753","article-title":"Affibody-based BCMA x CD16 dual engagers for activation of NK cells towards multiple myeloma","volume":"140","author":"Giang","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12248-022-00744-8","article-title":"Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, A novel anti-BCMA\/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma","volume":"24","author":"Cai","year":"2022","journal-title":"AAPS J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2023-190341","article-title":"Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) magnetismm studies","volume":"142","author":"Elmeliegy","year":"2023","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1182\/blood-2023-188080","article-title":"The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 monumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: A randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discovery"},{"key":"B102","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","article-title":"Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies","volume":"41","author":"Patel","year":"2023","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1394048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T05:20:12Z","timestamp":1712726412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1394048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":106,"alternative-id":["10.3389\/fonc.2024.1394048"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1394048","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"article-number":"1394048"}}